Biotech Values

[ghmm]

Yeah that too! But I don't see Raj as a financial genius or a gambler so believing he took the money while it was available I can believe. I think Dew has pointed out on this board the increased availability of funds in biotech this year [in response to a comment I posted a while back]. I think the financing boils down to Raj wanting to advance Eoquin AND Ozarelix alone in a more timely manner. Personally I would have preferred waiting a little then trying to partner.

Unless there is a (negative) suprise in the data I think this could actually be a very good opportunity for Satraplatin. It will allow for even more exposure. I wonder too if there is a feeling Doc's will use this (off-label) in front-line combo (with Taxotere) or stand-alone for patients who can't tolerate Taxotere so there is pressure to scrutinize the submission now. Keeping in mind this is an elderly population base so if you have efficacy anywhere near patients may prefer something that gives a better quality of life.